TCGA-DK-A2I4-01A-11R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 125.9855453
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- IL6_JAK_STAT3_SIGNALING+0.630
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.620
- INFLAMMATORY_RESPONSE+0.580
- TGF_BETA_SIGNALING+0.540
- COMPLEMENT+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ANGIOGENESIS+0.440
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- KRAS_SIGNALING_DN-0.310
- OXIDATIVE_PHOSPHORYLATION-0.310
- FATTY_ACID_METABOLISM-0.260
- SPERMATOGENESIS-0.210
- WNT_BETA_CATENIN_SIGNALING-0.180
- PEROXISOME-0.120
- PANCREAS_BETA_CELLS-0.110
- MYC_TARGETS_V1-0.060
- ADIPOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-2668-01A-01R-0946-07 | — | cohortA1 | 0.936 |
| 2 | SRR35579823 | — | D | 0.922 |
| 3 | SRR934741 | — | — | 0.921 |
| 4 | SRR934862 | — | — | 0.920 |
| 5 | TCGA-44-2668-01A-01R-A278-07 | — | cohortA1 | 0.917 |
| 6 | TCGA-98-7454-01A-11R-2045-07 | — | cohortMD2 | 0.912 |
| 7 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.906 |
| 8 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.902 |
| 9 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.901 |
| 10 | SRR10900560 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.580 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.540 | Inavolisib | — uncovered |
| COMPLEMENT | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |